The comparison sheet
whatisapeptide compares GHK-Cu, BPC-157 and semaglutide
A copper complex, a gastric fragment, a hormone ending and an engineered analogue. Sharing a chemical category leaves a great deal to specify.
GHK-Cu vs BPC-157
These molecules invite a comparison because repair appears in both literatures. The experiments give that word different content. BPC-157 improved biomechanical and functional recovery after rat Achilles-tendon transection. The GHK-Cu skin review describes collagen synthesis and topical human studies. I can't turn those into a head-to-head contest: the tissue, formulation and study populations differ.
| Molecule | Chemical detail | Human evidence here | Status |
|---|---|---|---|
| BPC-157 | 15-amino-acid synthetic gastric fragment | Three small pilot studies in the 2025 review | Unapproved research peptide |
| GHK-Cu | Gly-His-Lys bound to copper | Small topical studies; separate GHK mixture trial | Cosmetic ingredient; systemic use unapproved |
| KPV | Lys-Pro-Val hormone ending | No published clinical trials | Unapproved research peptide |
| Semaglutide | Modified 31-amino-acid GLP-1 analogue with fatty branch | Large randomised trials | FDA-approved prescription uses |
The BPC-157 clinical review and KPV review of preclinical work help locate those gaps. The chemistry gives me names precise enough to compare; the studies decide how far the comparison can go.
SURMOUNT-5: tirzepatide and semaglutide
This is an actual head-to-head trial. SURMOUNT-5 compared tirzepatide with semaglutide in 751 adults with obesity. At 72 weeks, mean weight change was -20.2% with tirzepatide and -13.7% with semaglutide. The difference was statistically significant.
STEP 1 answered another question. It found -14.9% with semaglutide and -2.4% with placebo at 68 weeks in adults with overweight or obesity without diabetes. The different semaglutide figures come from different trials. I resist splicing the most flattering numbers from separate studies into an imaginary contest.
Neither trial compared these medicines with BPC-157, GHK-Cu, KPV or a GLOW mixture. Their results cannot establish how those combinations would perform.
Semaglutide with BPC-157, GHK-Cu or GLOW
The studies listed here provide no controlled human evidence for combining semaglutide with BPC-157 or GHK-Cu, and no trial of a GLOW blend against semaglutide. Adding familiar names together produces a new experimental question. It also raises interaction and safety questions that separate studies leave unanswered.
Mixtures sometimes do get tested. The GHK-containing hair trial used free GHK plus 5-aminolevulinic acid; the KPV mouse study used nanoparticles combining KPV and an immunosuppressant. Each result attaches to its tested preparation and setting. Neither establishes a general rule that peptide combinations improve results.
A carefully specified combination trial would be worth following. At present, the honest comparison has empty spaces. For questions about a BPC-157 + GHK-Cu certificate of analysis, the FAQ examines what a sample document can establish.